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Most gastrointestinal stromal tumors (GISTs) contain activating mutations of the proto-oncogene c-kit. The GNNK isoform of c-kit has
a greater oncogenic potential than the GNNK+ isoform. We studied tumors from 29 patients with GIST, 19 of whom had c-kit mutations, and
compared them to normal cells and HMC-1 mast cell line. c-kit transcripts were quantified by real-time PCR. The ratios of GNNK/+
isoforms and of wild-type/mutant alleles were determined by RT-PCR and fluorometric quantification. On average, GISTs contained 1.9
times more c-kit transcripts than the HMC-1 cell line and GISTs with c-kit mutations contained 2.8 times more c-kit transcripts than those
without (P=0.003). The median GNNK/+ isoform ratios in GISTs with and without c-kit mutations were 4.4 and 4.1, respectively, and
there was no difference in the GNNK/+ ratios between the GISTs and the control samples. Both mutant and wild-type alleles of c-kit were
expressed in similar amounts in 13/15 mutant GISTs. The oncogenic effects of KIT in GISTs are not related to the higher expression level of
the GNNK isoform. The high expression level of both mutated and wild-type allele transcripts of c-kit suggests that interactions between
spontaneously activated and normal c-kit receptors are important in GIST tumorigenesis.
D 2004 Elsevier B.V. All rights reserved.Keywords: Proto-oncogene c-kit; Digestive system neoplasm; Mutation; RNA, Messenger; Isoform1. Introduction
KIT is a member of the type III tyrosine kinase
receptor family, which is the largest proto-oncogene
family [1]. c-kit is a transmembrane protein, the specific
ligand of which is the stem cell factor (SCF). This
receptor is involved in the growth and differentiation of
hematopoietic stem cells, mast cells, melanocytes, germi-0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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tumors, including small cell lung carcinomas, melanomas
and gastrointestinal stromal tumors (GIST), express c-kit
although only variable proportion of these tumors actually
do so [3].
Mutations of the c-kit gene have been observed in
mastocytosis, leukemia, seminomas and GIST [3]. These
mutations involve either the enzymatic domain or the juxta-
membrane domain of the receptor. The c-kit gene contains
21 exons [4] and two alternative splicing sites have been
described [5–7]. One of these alternative splicing sites is
located at the 3Vend of exon 9 and results in the expression
of two isoforms, designated GNNK and GNNK+. The two
isoforms have different biological activities. The GNNK
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transcript in several human malignant tumors [6,9].
GISTs are the most frequent mesenchymal tumors of
the digestive tract. They are characterized by the prolif-
eration of epithelioid or spindle cells expressing KIT [10].
Many GISTs contain c-kit mutations [11–20]. These
mutations are located within exons 11 and 9 in 50%
and 5% of cases, respectively. All exon 9 mutations are
in-frame insertions, whereas 85% of exon 11 mutations
are deletions or insertions and 15% are missense muta-
tions. Over 95% of exon 11 deletion or insertion muta-
tions are heterozygous [20]. Exon 11 mutations are
responsible for the spontaneous activation of c-kit and
thus are considered to be oncogenic [11]. Some familial
forms of GIST have been described and these are asso-
ciated with an activating mutation of c-kit [21,22], which
further supports the role of KIT in GIST oncogenesis. The
role of KIT in GIST was recently confirmed by the
finding that the tyrosine kinase inhibitor, imatinib mesy-
late, has strong anti-tumor effects [23,24]. This is one of
the first example of the successful treatment of a solid
tumor with an oncogene-targeted drug in humans. There-
fore, better knowledge of the role of KIT in GIST, and
particularly the expression of the GNNK oncogenic
variant and of the mutant alleles, may be useful for the
further development of oncogene inhibitors.
Thus, we studied the expression of c-kit transcripts in
GIST and compared it to the mutational status. Our results
provide new insights into GIST biology and suggest that
cellular models for the screening of new tyrosine kinase
inhibitor should co-express the mutant and wild-type
alleles.T2. Materials and methods
2.1. Patients
Twenty-nine GIST patients were included in the study.
Formalin-fixed and frozen tumor samples were available for
all the patients. Histological slides of all the patients were
reviewed by at least two pathologists (CJ, AC, ALS and
JFE). All cases were KIT-positive with immunohistochem-
istry, i.e., at least 5% of tumor cells were KIT-positive. None
of the patients received anti-tyrosine kinase therapy before
surgery.
Digestive tissue and blood samples were obtained from
10 control patients without GIST. Immunohistochemical
analysis of the digestive tissue sections revealed that the
small bowel and colon mucosa contained KIT-positive cells,
the morphology of which was compatible with mast cells,
and that the muscularis propria contained KIT-positive cells,
the morphology of which was compatible with interstitial
cells of Cajal and mast cells (data not shown).
All tissue and blood samples were obtained in accor-
dance with local ethical rules. Tumor samples were col-lected during surgical resection performed for therapeutic
purposes. The human mast cell line HMC-1 [25] was
kindly provided by Dr O. Hermine (Necker Institute,
Paris).
2.2. Quantification of c-kit transcripts
For RNA extraction, frozen tissues were mechanically
homogenized (Mixer Mill MM 300, Retsch, Germany).
RNA was extracted from tissue homogenates, leukocytes
and the HMC-1 cell line with the RNeasy and QIAshredder
kits (Qiagen, Courtaboeuf, France) according to the manu-
facturer’s instructions.
A maximum of 1-Ag RNA was reverse transcribed in a
20-Al final volume. The reaction mixture contained 1 RT
buffer, 5.5 mM MgCl2, 500 AM each dNTP, 2.5% random
hexamers, 0.4 U/Al RNase inhibitor and 1.25 U/Al reverse
transcriptase (Applied Biosystems, Foster City, USA). The
cycling conditions were 10 min at 25 jC, 30 min at 48 jC,
and 5 min at 95 jC. For all the samples, a control without
reverse transcriptase was performed in the same conditions.
For the standard curve, reverse transcription was performed
in the same conditions with dilutions of RNA from HMC-1
cell line. A new standard curve was prepared for each series
of samples.
Real-time PCR and subsequent calculations were per-
formed with the ABI Prism 7700 Sequence Detection
System (Applied Biosystems), which detects the signal
emitted from fluorogenic probes during PCR. Primers and
probes for the c-kit receptor cDNA were chosen with the
assistance of the Primer Express computer program (Applied
Biosystems). The specificity of the nucleotide sequences
chosen was confirmed by BLAST searches. To prevent the
amplification of contaminating genomic DNA, the two
primers bound to different exons. The sense primer TQ-F
(5VATTGGTA-TTTTTGTCCAGGAACTGA3V) was located
within exon 7, and the probe TQ-P (5VTGCTTCTGTACT-
GCTTCTGTACTGCCAGTG-GATGTGCA3V) and the an-
tisense primer TQ-R (5VTGGCCCAGATGAGTTTAGT-
GTCT3V) within exon 8 (Fig. 1). Taqman ribosomal RNA
control reagents (Applied Biosystems), designed for ribo-
somal S18 RNA amplification, were used as a reference to
normalize the results. PCR was performed with TaqMan
Universal PCR Master Mix reagents (Applied Biosystems).
The PCR mixture contained 1 TaqMan Universal PCR
Master Mix, 200 nM c-kit receptor forward and reverse
primers, 100 nM probe and 0.25 AMAmperase UNG (uracyl
N-glycosylase) in a total volume of 25 Al. A 2.5-Al volume of
reverse transcription product with or without reverse tran-
scriptase was used for each subsequent round of PCR. A
standard curve was constructed using 2.5-Al volumes of pure
and diluted (1:10, 1:100, 1:1000) cDNA from the HMC-1
cell line. After 2 min at 50 jC to permit UNG cleavage,
AmpliTaq Gold was activated by incubating for 10 min at 95
jC. Each of the 50 PCR cycles consisted of 15-s denaturation
at 95 jC and hybridization of probes and primers as well as
Fig. 1. Localization of the primers, probes, splicing sites and mutation sites within c-kit cDNA. The primers TQ-F and TQ-R as well as the probe TG-P were
used for real-time PCR. The primers AF and B were used for the quantification of GNNK /+ isorforms, while the primers AF and 12bis were used for the
quantification of both isoforms in mutated and non-mutated tumors.
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performed in triplicate for each standard and sample data
point. The amount of cDNA in each sample was calculated
by comparison with standard curves. Results are expressed
as the ratio of KIT mRNA to 18S RNA.
2.3. Detection of c-kit and PDGF receptor alpha mutations
DNA was extracted from paraffin-embedded or frozen
samples of the tumors after histological control, and cDNA
was obtained from frozen tumors. Mutations in exons 9 and
11 were detected on both genomic DNA and cDNA by length
analysis of PCR products (LAPP) and direct sequencing as
previously described [26]. Detection of mutations of the exon
13 and 17 of c-kit was performed by direct sequencing after
amplification with primers 5VGGCTTAATTAAGTCAGAT-
GGCTTAATTAAGTCAGATGC3Vand 5VCCTGCTTTGAA-
CAAATAAAT3V, and 5VACCAAGGCCGACAAAAGGA3V
and 5VCCAGACGTCACTTTCAAACGTG3V, respectively.
Detection of mutations of the PDGFRa gene was performed
by direct sequencing after amplification of exon 12 with
primers 5VGCACTGGGACTTTGGTAATTC 3Vand 5VGTA-
AAGTTGTGTGCAAGGG 3Vand of exon 18 with primers
5V ATGGCTTGATCCTGAGTCATT 3V and 5V GTG-
TGGGAAGTGTGGACG 3V.
2.4. Detection of RNA mutants and isoforms of c-kit
Isoforms of c-kit were detected by PCR amplification
using primers AF (5VCGATGTGGGCAAGACCTTCT3V)
and B (5VCAGCAAAGGAGTGAACAGG3V). Each of the
35 PCR cycles consisted of denaturation for 1 min at 92 jC,
annealing for 30 s at 58 jC and elongation for 45 s at 72 jC.
Each PCR included an initial denaturation step of 2 min at
94 jC and a final elongation step of 7 min at 72j. The
mutations and isoforms were simultaneously performed
using primers AF and 12bis (Fig. 1 and Table 1).
To detect the PCR FAM-labeled products and to deter-
mine their size, 1 Al of each sample was added to 23 Al of
formamide and 0.5 Al of GeneScan 500 TAMRA size
standard (Applied Biosystems). Capillary electrophoresis
was performed with an ABI Prism 310 apparatus, according
to the manufacturer’s instructions. Size curves and fluores-
cence intensity were analyzed and quantified with Genescan
software (Applied Biosystems).3. Results
The clinical characteristics of the patients with GIST are
presented in Table 1. All the tumors were KIT positive with
immunohistochemistry, and 26/29 (90%) were also CD34
positive (Table 1). Eighteen patients had an exon 11
mutation; twelve had an in-frame deletion, three had an
in-frame insertion and three had a point mutation. One
patient had an insertion within exon 9 of c-kit. Ten patients
did not have mutations in either exon 9, 11, 13 or 17 of c-
kit, two of which a deletion within exon 18 of PDGF
receptor alpha.
None of the control patients had mutations in exon 9 or
11 of c-kit.
3.1. Quantification of c-kit mRNA in GISTs
c-kit transcripts were quantified by real-time PCR and
the amount of c-kit transcripts expressed as the ratio of c-kit
to 18S RNA. The KIT/18S RNA ratio ranged from 0.01 to
8.35 (Fig. 2) and on mean the ratio was 1.9 times higher for
GISTs than for the HMC1 control cell line (2.95 versus
1.55, respectively). The median c-kit/18S ratio was higher
for GIST with c-kit mutations (3.67; range=0.74–8.35) than
for GIST without c-kit mutations (0.66; range=0.01–4.98),
and the mean ratios were 3.78 and 1.37, respectively
(P=0.003, Mann–Whitney test).
3.2. Expression of c-kit isoforms in GISTs and non-tumor
cells
RT-PCR was performed with primers flanking the splic-
ing site (Fig. 1) so that both the GNNK and + isoforms were
amplified simultaneously. Two peaks were detected for all
10 non-mutated GISTs. The positions of these peaks corre-
sponded to the expected lengths of both isoforms of the c-kit
transcript (Fig. 3). We always detected more of the GNNK
isoform than of the GNNK+ isoform, and the median
GNNK/+ ratio was 4.4 (range=2.4–12.7). As this ratio
may depend on the primers used, we performed another
PCR with the reverse primer 12bis, instead of B (Fig. 1). As
expected, the positions of both isoforms differed, but still
differed by 12 base pairs. The median GNNK/+ ratio was
4.2 (range=2.5–14.1), and the values were very similar to
those obtained with the first set of primers (Fig. 4) [inter-
Table 1
Characteristics of the patients with GIST
Number Age
(years)/
sex
Initial
localization
Size
(cm)
KIT CD34 c-kit
mutations
PDGFRa
mutations
71179 44/m Stomach 6 + + + + + no no
71103 46/m Colon 5 + + + + + no no
71105 73/m Peritoneum – + + + + no no
71176 78/m Intestine 3.5 + + + + + no no
71183 39/m Stomach 8 + + + + no no
71186 66/f Intestine – + + + + no no
71224 71/m Stomach 20 + + + + + no Del842–
845,
D846R,
S847V
71227 64/f Stomach 9.5 + + no Del843–
846,
S847I
71233 55/f Colon – + 0 no no
71385 49/m Intestine 22 + + + 0 no no
71175 69/m Stomach 11 + + + + + W557R no
71178 42/f Stomach 5 + + + + + V560D no
71386 57/f Stomach 6 + + + + + + V560D no
71231 57/m Intestine 9 + + + Del
557–558
plus
V559C
no
71237 67/m Stomach 25 + + + + + Del
561–578
no
71239 54/f Stomach – + + + + + Del
555–558
no
71100 46/f Stomach 25 + + + + + + Del
553–558
no
71101 77/m Stomach 8 + + + + Del 576 no
71177 65/m Stomach 3 + + + + + + Del 550
plus
P551I
no
71184 66/f Stomach 5 + + + + + Del
557–562
no
71185 56/f Stomach 7 + + + + + Del 579 no
71187 66/m Mesentery 40 + + + + + Ins
574–591
no
71225 57/f Stomach 9 + + + + + Del
552–558
plus
V559I
no
71228 73/f Stomach 11 + + + + Ins
572–584
no
71229 54/f Stomach 4 + + + + + Del 576 no
71232 64/m Intestine 12 + + + + + + Del
557–558
no
71234 45/f Intestine – + + + 0 Ins
573–587
no
71238 65/f Stomach 10 + + + + + Del
550–558
no
71181 64/f Intestine 3 + + + + Ins
502–503
no
M: male; f: female; E-11: exon 11; E-9: exon 9; PM: point mutation; D:
deletion; I: insertion.
+: 5% to 20% of positive tumor cells; ++: 21% to 80% of positive tumor
cells; +++: more than 80% of positive tumor cells.
Fig. 2. Real-time PCR quantification of c-kit mRNA in GIST with either
wild-type (wt) or mutated (mutant) c-kit. The amount of c-kit mRNA is
expressed as a ratio (c-kit mRNA/18S RNA). Each point corresponds to the
average of three measurements for one tumor. The HMC-1 human mast cell
line was used as a reference.
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(0.87–0.99)]. The median GNNK/+ ratio of the exon
11-mutated GISTs (n=18) was 4.1 (range=2.3–6.3) (Fig. 4).
We also analyzed peripheral blood leukocytes (n=4),
and micro-dissected mucosa and muscularis propria from
the small intestine (n=4) and colon (n=2) of control
patients. RT-PCR of each sample revealed two peaks, the
positions of which corresponded to the expected lengths ofFig. 3. Quantification of c-kit isoforms by fluorescence intensity after RT-
PCR. Fluorescent amplicons (blue peaks) were separated by capillary
electrophoresis and identified on the basis of their size. The respective sizes
of each peak were quantified from their corresponding fluorescence
intensity. The red peaks correspond to size markers (TAMRA). The three
figures correspond to three different non-mutated GISTs. GNNK :
GNNK isoform. GNNK+: GNNK+ isoform.
Fig. 4. GNNK /+ isoform ratios in control cells and GISTs. Mast cells: RNA extracted from either blood cells or mucosa of the ileum and colon. ICC: RNA
extracted from digestive muscularis propria in which interstitial cells of Cajal and mast cells were the only KIT positive cells. wt: wild-type. AFB, AF12bis:
amplification with the corresponding sets of primers.
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was always more abundant. The median GNNK/+ ratios
of mast cells (i.e. blood leukocytes and digestive mucosa)
and digestive muscularis propria (containing interstitial
cells of Cajal and mast cells) were 7.36 (range=4.29–
27.31) and 5.94 (range=4.30–7.29), respectively (Fig. 4).
The GNNK/+ ratios of control digestive muscularis
propria, wild-type GISTs and mutated GISTs were not
significantly different (Kruskall–Wallis test P=0.065).Fig. 5. Quantification of c-kit wild-type and mutant transcripts and their
isoforms by fluorescence intensity after RT-PCR. Fluorescent amplicons
(blue peaks) were separated by capillary electrophoresis and identified on
the basis of their size. The respective sizes of each peak were determined
from their corresponding fluorescence intensity. The red peaks correspond
to size markers (TAMRA). The four figures correspond to three different
mutated GISTs. Wt : GNNK isoform of the wild-type transcript.
Wt + : GNNK+ isoform of the wild-type transcript. M : GNNK
isoform of the mutant transcript. M+: GNNK isoform of the mutant
transcript.3.3. Transcription of KIT mutants
As most c-kit mutations were heterozygous, we com-
pared the transcription of wild-type and mutated alleles of c-
kit by performing a RT-PCR with primers flanking the
deleted region of exon 11 (Fig. 1). The wild-type and
mutated alleles of the 16 GISTs with deletion or insertion
mutations in c-kit could thus be identified on the basis of
their size.
In 13 out of the 16 cases, four peaks were detected, with
the expected nucleotide lengths of both isoforms of the
mutated and wild-type alleles (Fig. 5). The positions of each
peak allowed us to identify precisely the isoforms of either
the mutated or wild-type allele. In these 13 cases, the wild-
type and mutated alleles contained similar amounts of
GNNK [interclass correlation coefficient of 0.92, confi-Fig. 6. Comparison of the amount of GNNK isoform of wild-type and
mutant allele transcripts in GISTs. Au: arbitrary units corresponding to the
fluorescent intensity of the GNNK peaks.
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GNNK/+ isoform ratios of the wild-type and mutated
alleles were compared for each tumor whenever it was
possible to quantify GNNK+ peaks (n=13). The median
GNNK/+ ratios were 4.6 (range=1.8–7.4) and 4.3
(range=1.9–5.9) for mutated and wild-type alleles, respec-
tively (Fig. 4).
In 1 of the 16 cases, the mutation consisted of a 12-base-
pair deletion and only three peaks were detected, one of
which corresponded to the fusion of the GNNK wild-type
and GNNK+ mutated alleles.
In 2 of the 16 cases, only two peaks were detected,
corresponding to the mutated alleles in both cases. In these
tumors, the c-kit mRNA/18S RNA ratio was 3.44 and 2.65.
Analysis of genomic DNA revealed that the wild-type allele
was almost undetectable in one case, but was present in
similar amounts as the mutant allele in the other case.4. Discussion
In this study, we quantified isoforms of wild-type and
mutant transcripts of c-kit in 29 GISTs, 19 of which had a
KIT-activating mutation. We showed that mutant GISTs
contained significantly more c-kit transcripts than those
without mutations. The GNNK isoform of c-kit, which
is more oncogenic than the GNNK+ isoform, was predom-
inant in wild-type and mutant GISTs. However, the
GNNK/+ ratios were similar to in normal interstitial cells
of Cajal and mast cells. Finally, in most mutant GISTs,
similar amounts of both wild-type and mutant alleles were
expressed.
The median amount of c-kit mRNAwas higher in GISTs
than in the control HMC-1 mast cell line. HMC-1 is a cell
line derived from a human mast cell leukemia that consti-
tutionally expresses KIT and has an activating mutation of
c-kit [27]. It has been extensively used for the study of KIT
activation and signaling pathways [28,29]. Our data thus
confirm that most GISTs express high levels of KIT.
Interestingly, the amount of c-kit mRNA was 2.8 times
higher in mutated than in wild-type GISTs (P=0.003). This
is not because c-kit mutant transcripts are more stable, as
similar amounts of both alleles were present in most mutated
tumors. Furthermore, both tumors in which only the mutated
transcript was present contained less c-kit mRNA than the
median level found in mutated GISTs. The lower expression
of KIT in non-mutated GISTs without mutations suggests
that their growth could be partly sustained by other onco-
genes. Indeed, activating mutations of the PDGF receptor
alpha have recently been published [30], and were present in
two cases of our series. The lack of wild-type c-kit mRNA
in two cases probably results from complex mechanisms, as
wild-type genomic DNA was present in one and undetect-
able in the other.
The GNNK and GNNK+ isoforms have several func-
tional differences. When transiently expressed in COS cells,GNNK, but not GNNK+, murine KIT displays constitu-
tive tyrosine phosphorylation [5]. Transfection of human
NIH3T3 cells with GNNK leads to loss of contact
inhibition in vitro and tumorigenicity in nude mice, whereas
transfection with GNNK+ does not [8]. This could be
related to differences in the activation of c-Src kinase
depending on the GNNK isoform [31]. Both the GNNK
and + isoforms have been detected in several human tissues
and tumors including GISTs [6,9,32]. The GNNK isoform
tends to be predominant and some authors have suggested
that its higher oncogenic potential could at least partly
explain tumor growth [32]. Our results that GNNK was
4.1 to 4.6 times more abundant than GNNK+ in GISTs,
whatever their mutation status. However, the GNNK/+
ratio in GISTs was not different from that of normal
interstitial cells of Cajal. Similarly, Piao et al. [9] have
determined the GNNK/+ ratio in normal human bone
marrow cells and acute myelogenous leukemia by means
of the RNase protection analysis and obtained identical
results to ours (mean ratios of 4.8 and 4.2, respectively).
Thus, the abundance of the GNNK isoform cannot explain
the oncogenic transformation of either interstitial cells of
Cajal or blood stem cells.
The tyrosine kinase receptor family is one of the largest
oncogene families [1]. Activating mutations have been
observed in several tyrosine kinase receptors including
KIT, TGFR-beta, Flt3 and ret. The mutations are generally
heterozygous, as is the case in 95% of mutated GISTs [20].
However, few data have been published concerning the
transcription of mutant and wild-type alleles. Furthermore,
transfection experiments have only been performed with
the mutant allele, rather than with a co-transfected wild-
type allele [11]. We detected the same amount of mutant
and wild-type transcripts in 13 of the 15 tumors that could
be studied. Thus, the presence of a mutation in an allele of
the c-kit gene does not result in the cis regulation of its
own transcription and does not affect the degradation rate
of its transcript. Our data also suggest that wild-type and
mutated KIT receptors are expressed in similar amounts in
these tumors. Anti-tyrosine kinase receptor antibodies and
tyrosine kinase receptor inhibitors were recently shown to
induce tumor regression in some patients [23,24] and many
other tyrosine kinase inhibitors are currently being tested.
Our data suggest that cellular models for the screening of
new tyrosine kinase inhibitors and for the analysis of
tumor biology should co-express the mutant and wild-type
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